Design Therapeutics (DSGN) Other Accumulated Expenses (2020 - 2021)
Design Therapeutics (DSGN) posted quarterly Other Accumulated Expenses of $239000.0 for Q2 2021, up 25.13% on a QoQ basis from $191000.0 in Q1 2021.
Powered by 
Analysis
Design Therapeutics (DSGN) Other Accumulated Expenses (2020 - 2021) Analysis & Trends
Design Therapeutics has reported Other Accumulated Expenses for 2 years, with the latest figure at $239000.0 in Q2 2021.
- Other Accumulated Expenses for Q2 2021 came in at $239000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $239000.0 (changed N/A YoY), and the FY2020 annual result was $100000.0, changed N/A from the prior year.
- Other Accumulated Expenses climbed to $239000.0 in Q2 2021, from $191000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $239000.0 in Q2 2021 and troughed at $100000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 239,000.00 |
| Mar 31, 2021 | 191,000.00 |
| Dec 31, 2020 | 100,000.00 |